![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TOR1AIP2 |
Gene summary for TOR1AIP2 |
![]() |
Gene information | Species | Human | Gene symbol | TOR1AIP2 | Gene ID | 163590 |
Gene name | torsin 1A interacting protein 2 | |
Gene Alias | IFRG15 | |
Cytomap | 1q25.2 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | A0A024R957 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
163590 | TOR1AIP2 | LZE2T | Human | Esophagus | ESCC | 1.96e-05 | 5.84e-01 | 0.082 |
163590 | TOR1AIP2 | LZE4T | Human | Esophagus | ESCC | 5.38e-12 | 4.24e-01 | 0.0811 |
163590 | TOR1AIP2 | LZE7T | Human | Esophagus | ESCC | 3.91e-15 | 3.82e-01 | 0.0667 |
163590 | TOR1AIP2 | LZE8T | Human | Esophagus | ESCC | 5.68e-10 | 3.54e-01 | 0.067 |
163590 | TOR1AIP2 | LZE20T | Human | Esophagus | ESCC | 7.06e-08 | 1.39e-01 | 0.0662 |
163590 | TOR1AIP2 | LZE22T | Human | Esophagus | ESCC | 1.85e-03 | 3.85e-01 | 0.068 |
163590 | TOR1AIP2 | LZE24T | Human | Esophagus | ESCC | 5.08e-13 | 2.91e-01 | 0.0596 |
163590 | TOR1AIP2 | LZE21T | Human | Esophagus | ESCC | 2.85e-06 | 2.96e-01 | 0.0655 |
163590 | TOR1AIP2 | P1T-E | Human | Esophagus | ESCC | 6.09e-08 | 4.17e-01 | 0.0875 |
163590 | TOR1AIP2 | P2T-E | Human | Esophagus | ESCC | 3.62e-16 | 3.69e-01 | 0.1177 |
163590 | TOR1AIP2 | P4T-E | Human | Esophagus | ESCC | 3.41e-29 | 5.38e-01 | 0.1323 |
163590 | TOR1AIP2 | P5T-E | Human | Esophagus | ESCC | 3.92e-29 | 5.30e-01 | 0.1327 |
163590 | TOR1AIP2 | P8T-E | Human | Esophagus | ESCC | 2.62e-18 | 3.53e-01 | 0.0889 |
163590 | TOR1AIP2 | P9T-E | Human | Esophagus | ESCC | 6.19e-16 | 4.14e-01 | 0.1131 |
163590 | TOR1AIP2 | P10T-E | Human | Esophagus | ESCC | 1.24e-16 | 3.89e-01 | 0.116 |
163590 | TOR1AIP2 | P11T-E | Human | Esophagus | ESCC | 2.77e-12 | 8.30e-01 | 0.1426 |
163590 | TOR1AIP2 | P12T-E | Human | Esophagus | ESCC | 4.15e-09 | 1.82e-01 | 0.1122 |
163590 | TOR1AIP2 | P15T-E | Human | Esophagus | ESCC | 7.88e-23 | 3.95e-01 | 0.1149 |
163590 | TOR1AIP2 | P16T-E | Human | Esophagus | ESCC | 6.45e-21 | 3.60e-01 | 0.1153 |
163590 | TOR1AIP2 | P17T-E | Human | Esophagus | ESCC | 5.50e-07 | 2.34e-01 | 0.1278 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034504110 | Skin | cSCC | protein localization to nucleus | 143/4864 | 290/18723 | 8.98e-18 | 1.02e-15 | 143 |
GO:00070296 | Skin | cSCC | endoplasmic reticulum organization | 42/4864 | 87/18723 | 6.36e-06 | 8.92e-05 | 42 |
GO:00327816 | Skin | cSCC | positive regulation of ATPase activity | 15/4864 | 27/18723 | 1.03e-03 | 6.94e-03 | 15 |
GO:00434628 | Skin | cSCC | regulation of ATPase activity | 22/4864 | 46/18723 | 1.16e-03 | 7.61e-03 | 22 |
GO:0034504111 | Thyroid | PTC | protein localization to nucleus | 170/5968 | 290/18723 | 3.34e-21 | 6.38e-19 | 170 |
GO:000702915 | Thyroid | PTC | endoplasmic reticulum organization | 51/5968 | 87/18723 | 2.37e-07 | 4.15e-06 | 51 |
GO:00434629 | Thyroid | PTC | regulation of ATPase activity | 23/5968 | 46/18723 | 7.89e-03 | 3.33e-02 | 23 |
GO:00327817 | Thyroid | PTC | positive regulation of ATPase activity | 15/5968 | 27/18723 | 9.19e-03 | 3.79e-02 | 15 |
GO:003450423 | Thyroid | ATC | protein localization to nucleus | 175/6293 | 290/18723 | 6.23e-21 | 1.23e-18 | 175 |
GO:000702921 | Thyroid | ATC | endoplasmic reticulum organization | 51/6293 | 87/18723 | 1.47e-06 | 1.81e-05 | 51 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TOR1AIP2 | SNV | Missense_Mutation | c.648N>T | p.Trp216Cys | p.W216C | Q8NFQ8 | protein_coding | deleterious(0.03) | benign(0.012) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD | |
TOR1AIP2 | SNV | Missense_Mutation | novel | c.724N>G | p.Pro242Ala | p.P242A | Q8NFQ8 | protein_coding | deleterious(0.02) | benign(0.192) | TCGA-C5-A905-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TOR1AIP2 | SNV | Missense_Mutation | c.314N>T | p.Ser105Leu | p.S105L | Q8NFQ8 | protein_coding | tolerated_low_confidence(0.05) | benign(0.018) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
TOR1AIP2 | SNV | Missense_Mutation | novel | c.667N>G | p.Leu223Val | p.L223V | Q8NFQ8 | protein_coding | tolerated(0.26) | benign(0.015) | TCGA-RA-A741-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
TOR1AIP2 | SNV | Missense_Mutation | c.1091N>A | p.Val364Glu | p.V364E | Q8NFQ8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
TOR1AIP2 | SNV | Missense_Mutation | rs772272447 | c.469G>C | p.Asp157His | p.D157H | Q8NFQ8 | protein_coding | deleterious(0) | possibly_damaging(0.726) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
TOR1AIP2 | SNV | Missense_Mutation | novel | c.334C>T | p.Pro112Ser | p.P112S | Q8NFQ8 | protein_coding | tolerated_low_confidence(0.29) | benign(0.033) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TOR1AIP2 | SNV | Missense_Mutation | rs200952880 | c.832N>T | p.Arg278Trp | p.R278W | Q8NFQ8 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
TOR1AIP2 | SNV | Missense_Mutation | c.799C>T | p.Pro267Ser | p.P267S | Q8NFQ8 | protein_coding | deleterious(0.01) | probably_damaging(0.939) | TCGA-AY-6196-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
TOR1AIP2 | SNV | Missense_Mutation | c.584N>C | p.Lys195Thr | p.K195T | Q8NFQ8 | protein_coding | tolerated(0.63) | benign(0.012) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |